Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET

Company Participants

Chris Taylor - Vice President, Investor Relations and Corporate Communications
Brian Goff - Chief Executive Officer
Sarah Gheuens - Chief Medical Officer and Head, R&D
Tsveta Milanova - Chief Commercial Officer
Cecilia Jones - Chief Financial Officer

Conference Call Participants

Eric Schmidt - Cantor
Christopher Raymond - Piper Sandler
Gregory Renza - RBC Capital Markets
Divya Rao - TD Cowen
Tess Romero - JP Morgan
Alec Stranahan - Bank of America

Operator

Good morning, and welcome to Agios' Second Quarter 2024 Conference Call. [Operator Instructions]. Please be advised that today's call is being recorded at Agios' request.

I would now like to turn the call over to Chris Taylor, Vice President, Investor Relations and Corporate Communications for Agios.

Chris Taylor

Thank you, operator. Good morning, everyone, and welcome to Agios' conference call and webcast to discuss second quarter 2024 financial results and recent business highlights. You can access slides for today's call by going to the Investors section of our website, agios.com.

On today's call, I’m joined by our Chief Executive Officer, Brian Goff; Dr. Sarah Gheuens, Chief Medical Officer and Head of Research and Development; Tsveta Milanova, our Chief Commercial Officer; and Cecilia Jones, Chief Financial Officer.

Before we get started, I would like to remind everyone that, some of the statements we make on this call will include forward-looking statements. Actual results and events could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC.

With that, I'm pleased to turn the call over to Brian.

Brian Goff

Thanks Chris. Good morning, everyone, and thank you for joining us. Our mission at Agios is to develop and deliver transformative medicines that elevate and extend the lives of patients living with rare diseases. Our foundation leverages mitapivat's novel mechanism of action, which improves overall red blood cell health and has been a key driver of our positive clinical data readouts in recent years.

I'm delighted to report that, we continued our positive momentum in Q2 with multiple key milestones announced this quarter. First, we announced that the Phase 3 ENERGIZE-T study of mitapivat met both the primary endpoint and all key secondary endpoints in adults, with transfusion-dependent alpha or beta-thalassemia. Importantly, ENERGIZE-T is the first Phase 3 study to demonstrate efficacy of an oral disease-modifying treatment for transfusion-dependent alpha and beta-thalassemia.